AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Background

Bacterial gastroenteritis is a very common disorder. It has many causes, can range from mild to severe, and usually manifests with symptoms of vomiting, diarrhea, and abdominal discomfort. Other causes of some of these symptoms include viral infections, improper diet, malabsorption syndromes, various enteropathies, and inflammatory bowel disease. Bacterial gastroenteritis usually is self-limited, but improper management of an acute infection can lead to a protracted course. By far, the most common complication is dehydration.

Pathophysiology

Bacteria employ several mechanisms to invoke a pathologic response. Invasive bacteria cause mucosal ulceration and abscess formation with a subsequent inflammatory cascade. Bacterial toxins control enteral and extraenteral cellular processes. For example, the heat-labile and heat-stable enterotoxins of Escherichia coli activate enteral adenylate cyclase and guanylate cyclase. Verotoxin, which enterohemorrhagic E coli and Shigella species produce, causes systemic disorders such as seizures and hemolytic-uremic syndrome (HUS). Other noninvasive bacteria adhere to the gut wall, causing inflammation. Organisms such as E coli and Clostridium species are normal enteric flora, pathogenic strains of which can cause gastroenteritis.

Frequency

United States

Bacterial gastroenteritis is a very common problem in primary care and emergency department settings, especially for children younger than 5 years. Diarrhea accounts for as many as 5% of pediatric office visits and 10% of hospitalizations in this age group. Very often, gastroenteritis is underreported in the adult population. Each year, gastroenteritis affects every adult and accounts for 8 million doctor visits and 250,000 hospitalizations. Episodes of gastroenteritis do not occur at random but usually occur in outbreaks. Traveler's diarrhea affects 20-50% of people traveling from industrialized to developing countries.

International

Worldwide, millions of children and adults are affected by diarrhea each year. In developing countries, where sanitation is suboptimal, epidemics of bacterial gastroenteritis can develop and cause significant mortality.

Mortality/Morbidity

Diarrhea and vomiting are so commonplace that nonphysicians usually underappreciate the potential mortality and morbidity of bacterial gastroenteritis. In the United States each year, several hundred people die from complications of bacterial gastroenteritis; the majority are elderly people. Many developing countries do not have the resources to properly treat diarrhea and vomiting associated with bacterial gastroenteritis, leading to a disproportionately high mortality rate. Gastroenteritis-causing pathogens are the second leading cause of morbidity and mortality worldwide.

Race

For example, it has been reported that the preparation and ingestion of chitterlings, common among some African Americans, especially during the holiday season, may pose an increased risk of infection with Yersinia enterocolitica serotype O:3.

Sex

Most infectious diarrheas do not affect one sex more than the other; however, females have a higher incidence of Campylobacter infections and HUS.

Age

Yersinia species infect children younger than 1 year almost exclusively, and Aeromonas species are a significant cause of bacterial gastroenteritis in young children. Very young children are particularly susceptible to secondary dehydration and malabsorption.

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

History

• Stool characteristics
• • Diarrhea is defined as daily stools with a mass greater than 15 g/kg for children younger than 2 years and greater than 200 g for children aged 2 years and older. Adult stool patterns vary from 1 stool every 3 days to 3 stools per day; therefore, consider individual stool patterns.
  • Consistency, color, volume, and frequency are very important in determining whether the source is from the small or large bowel. Table 1 outlines these characteristics and demonstrates that an index of suspicion can be generated easily for a specific set of organisms.

  Table 1. Stool Characteristics and Determining Their Source

  Stool Characteristics	Small Bowel	Large Bowel
  Appearance	Watery	Mucus and/or blood
  Volume	Large	Small
  Frequency	Increased	Increased
  Blood	Possibly heme-positive but never gross blood	Possibly grossly bloody
  pH	Possibly <5.5	>5.5
  Reducing substances	Possibly positive	Negative
  WBC count	<5/HPF*	Possibly >10/HPF
  Serum WBC count	Normal	Possible leukocytosis, bandemia
  Organisms	Preformed toxins Bacillus species, Staphylococcus aureus	Invasive bacteria E coli and Shigella, Salmonella, Campylobacter, Yersinia, Aeromonas, and Plesiomonas species
  	Toxic bacteria E coli, cholera, Clostridium perfringens, Vibrio species, Listeria monocytogenes	Toxic bacteria Clostridium difficile
  	Other causes Rotavirus, Adenovirus, Calicivirus, Astrovirus, Norwalk virus, Giardia and Cryptosporidium species	Other causes Entamoeba species

  *High-power field

• Associated systemic symptoms can guide empiric therapy. Some enteric infections have characteristic systemic symptoms, while associated systemic features of others do not occur reliably. Table 2 outlines the frequency of these symptoms with various organisms.
• Onset and duration characteristics can narrow the differential diagnosis of the organism. Onset of symptoms within 6 hours of exposure to the bacterial source indicates a preformed toxin, probably produced by Staphylococcus or Bacillus species. Table 2 outlines incubation and duration characteristics of common bacteria.

Table 2. Organisms and Frequency of Symptoms

• Particular foods are associated with certain bacteria. Ingestion of raw or contaminated food, particularly raw milk and meat, is a common cause of bacterial gastroenteritis. The following list outlines organisms that cause food poisoning:
• • Dairy - Campylobacter, Salmonella, Listeria, and Staphylococcus species
  • Eggs - Salmonella species
  • Meats - C perfringens and Salmonella, Aeromonas, Campylobacter, and Staphylococcus species
  • Ground beef - Enterohemorrhagic E coli
  • Poultry - Campylobacter species
  • Pork - C perfringens and Y enterocolitica
  • Seafood - Aeromonas, Plesiomonas, and Vibrio species and Astrovirus
  • Oysters - Plesiomonas and Vibrio species and Calicivirus
  • Vegetables - Aeromonas species and C perfringens
  • Alfalfa sprouts - Enterohemorrhagic E coli and Salmonella species
  • Fried rice - Bacillus species
  • Custards, mayonnaise - Staphylococcus species
• Water is a major reservoir for many organisms that cause diarrhea. Swimming pools have been associated with outbreaks of Shigella organisms, and Aeromonas species are associated with exposure to the marine environment.
• Travel history is an important and useful clue in determining bacterial etiology. Enterotoxigenic E coli is the leading cause of traveler's diarrhea. Rotavirus and Shigella, Salmonella, and Campylobacter species are prevalent worldwide and need to be considered regardless of specific travel history. Other organisms that are prevalent in particular parts of the world are listed below. The risk of contracting diarrhea while traveling is highest in travel to Africa. Travel to Portugal, Spain, and Eastern European countries also is associated with a relatively high risk. Organisms associated with travel to particular locations are as follows:
• • Nonspecific - Enterotoxigenic E coli and Aeromonas, Giardia, Plesiomonas, Salmonella, and Shigella species
  • Underdeveloped tropics - C perfringens
  • Africa - Entamoeba species and V cholerae
  • Americas (South and Central) - Entamoeba species and V cholerae
  • Asia - V cholerae
  • Australia - Yersinia species
  • Canada - Yersinia species
  • Europe - Yersinia species
  • India - Entamoeba species and V cholerae
  • Japan - Vibrio parahaemolyticus
  • Mexico - Aeromonas, Entamoeba, Plesiomonas, and Yersinia species
  • New Guinea - Clostridium specie
• Animals can transmit particular bacteria. Exposure to young dogs or cats is associated with Campylobacter transmission. Exposure to turtles is associated with Salmonella transmission.
• Preexisting medical conditions can predispose for infections with particular organisms. The following list outlines such medical conditions and their associated organisms:
• • C difficile - Hospitalization with antibiotic administration
  • Plesiomonas species - Liver diseases or malignancy
  • Salmonella species - Intestinal dysmotility, malnutrition, achlorhydria, hemolytic anemia (especially sickle cell disease), immunosuppression, and malaria
  • Rotavirus - Hospitalization
  • Giardia species - Agammaglobulinemia, chronic pancreatitis, achlorhydria, and cystic fibrosis
  • Cryptosporidia - Immunocompromise and immunosuppression
• Outbreaks are caused by particular bacteria, including enterohemorrhagic E coli O157:H7, Listeria monocytogenes, C perfringens, and Salmonella species.

Physical

• Dehydration is the primary cause of morbidity and mortality. Assess every patient for signs, symptoms, and severity. Lethargy, depressed consciousness, dry mucous membranes, sunken eyes, poor skin turgor, and delayed capillary refill should raise suspicion of dehydration.
• Malnutrition typically is a sign of a chronic process. Reduced muscle and fat mass is found. This usually is due to development of secondary carbohydrate intolerance.
• Abdominal pain is a common symptom in gastroenteritis. Nonspecific nonfocal abdominal pain and cramping are common with some organisms. This pain usually does not increase with palpation. Focal abdominal pain worsened by palpation, rebound tenderness, or guarding should alert the clinician to possible complications or to another noninfectious GI diagnosis.
• Borborygmi, defined as a significant increase in peristaltic activity with small bowel diarrhea, can cause an audible and/or palpable increase in bowel activity.
• Perianal erythema results from many stools causing a constantly wet area. Failure to properly dry the buttocks and perianal area results in erythema and skin breakdown.

Causes

• Salmonella, Shigella, and Campylobacter species are the top 3 leading causes of bacterial diarrhea worldwide, followed closely by Aeromonas species.
• Aeromonas and Shigella infection have a higher incidence in summer and fall, and Campylobacter infection usually occurs in summer months.
• Yersinia infection occurs most frequently in winter months and colder climates.

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Lab Studies

• Stool pH of 5.5 or below or the presence of reducing substances indicates carbohydrate intolerance. This usually is transient in nature.
• Enteroinvasive infections of the large bowel cause leukocytes, predominantly neutrophils, to be shed into stool. Absence of fecal leukocytes does not eliminate the possibility of enteroinvasive organisms; however, the presence of fecal leukocytes eliminates consideration of enterotoxigenic E coli, Vibrio species, and viruses.
• Examine any exudate found in the stool for leukocytes. Such exudates highly suggest inflammatory bowel disease, which could be infectious or of another origin, eg, inflammatory bowel disease.
• Table 3 lists common bacteria and the optimal culture mediums for their growth.

  Table 3. Common Bacteria and Optimum Culture Mediums

  Organism	Detection Method	Microbiological Characteristics
  Aeromonas species	Blood agar	Oxidase-positive, flagellated GNBa
  Bacillus species	Blood agar	Facultatively aerobic, spore-forming GPRb; beta-hemolytic; reduces nitrates; ferments carbohydrates
  Campylobacter species	Skirrow agar	Rapidly motile, curved GNRc; Campylobacter jejuni 90% of infections, Campylobacter coli 5% of infections
  C difficile	CCFEd agar, EIAe for toxin, LAf for protein	Anaerobic, spore-forming GPR; toxin-mediated diarrhea; produces pseudomembranous colitis
  C perfringens	None available	Anaerobic, spore-forming GPR; toxin-mediated diarrhea
  E coli	MacConkey, EMBg, or SMh agar	Lactose-producing GNR
  Listeria species	Blood agar	Flagellated GPBi
  Plesiomonas species	Blood agar	Oxidase-positive GNR
  Salmonella species	Blood, MacConkey, EMB, XLDj, or HEk agar	Nonlactose, non–H2S-producing GNR
  Shigella species	Blood, MacConkey, EMB, XLD, or HE agar	Nonlactose and H2S-producing GNR; verotoxin (neurotoxin)
  Staphylococcus species	Blood agar	Heat-stable, preformed toxin-mediated GPCl
  Vibrio species	Blood or TCBSm agar	Oxidase-positive, motile, curved GNB
  Y enterocolitica	CINn agar	Nonlactose-producing, oval GNR

  ^a Gram-negative bacillus
  ^b Gram-positive rod
  ^c Gram-negative rod
  ^d Cycloserine-cefoxitin-fructose-egg
  ^e Enzyme immunoassay
  ^f Latex agglutination
  ^g Eosin-methylene blue
  ^h Sorbitol-MacConkey
  ⁱ Gram-positive bacillus
  ^j Xylose-lysine-deoxycholate
  ^k Hektoen enteric
  ^l Gram-positive cocci
  ^m Thiosulfate-citrate-bile-sucrose
  ⁿ Cefsulodin-Irgasan-novobiocin
• The following is a list of the different culture mediums used to isolate bacteria. A high index of suspicion is needed to choose the appropriate medium.
  • Blood agar - All aerobic bacteria and yeast; detects cytochrome oxidase production
  • MacConkey EMB agar - Inhibits gram-positive organisms; permits lactose fermentation
  • XLD agar and HE agar - Inhibit gram-positive organisms and nonpathogenic gram-negative bacilli; permit lactose fermentation and H2S production
  • Skirrow agar - Selective for Campylobacter species
  • SM agar - Selective for enterohemorrhagic E coli
  • CIN agar - Selective for Y enterocolitica
  • Thiosulfate-citrate-bile-sucrose agar - Selective for Vibrio species
  • CCFE agar - Selective for C difficile
• Stool cultures are useful when positive, but the yield usually is low.
• • Refrigerate stool not cultured within 2 hours of collection at 4°C, or place it in transport medium.
  • Always culture stool for Campylobacter, Salmonella, and Shigella species, especially if stool leukocytes or gross blood is found in the stool.
• Serotype Salmonella for typhimurium DT104, particularly if associated with raw milk or cheese ingestion. Salmonella typhimurium DT104 is a multidrug-resistant organism, and antibiotic sensitivities are crucial to guide therapy.
• Preformed toxin from Bacillus or Staphylococcus may cause rapid-onset gastroenteritis. In such cases, the bacteria may not exist in the GI tract; therefore, culture the food ingested by the person.
• Bloody diarrhea with a history of ground beef ingestion should raise suspicion for enterohemorrhagic E coli. If E coli is found in the stool, type it to determine if it is O157:H7. Report cases of E coli O157:E7 gastroenteritis (and other infectious problems) to the state health department.
• History of raw seafood ingestion or foreign travel should prompt additional screening for Vibrio and Plesiomonas species.
• Leukocyte count usually is not elevated in viral and toxin-mediated diarrhea. Leukocytosis is seen with enteroinvasive bacteria. Shigella characteristically causes marked bandemia with variable total WBC count.
• Antilisteriolysin O is positive during the convalescent phase of the illness and when invasive disease has occurred.

Procedures

• Identification of pseudomembranes in the colon by direct visualization is diagnostic for C difficile; however, the yield may be low.

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical Care

Because most infectious diarrhea is self-limited, medical care primarily is supportive in nature. Oral rehydration is the mainstay of treatment. Young infants and neonates are at high risk for secondary complications and require close monitoring, as do older individuals. Consider intravenous rehydration when oral rehydration is unsuccessful. Particular attention must be paid to repletion of potassium as needed.

• Oral rehydration therapy is the cornerstone of diarrhea treatment, especially for small bowel infections that produce a large volume of watery stool output. Studies confirm that early refeeding hastens recovery. Many commercial oral rehydration formulas are available and have been designed to promote optimal absorption of nutrients. Administer maintenance fluids plus replacement of losses to ill children. Administer small amounts of fluid at frequent intervals in order to minimize discomfort and vomiting. A 5- or 10-cc syringe without a needle is a very useful tool. The syringe can be used to place small amounts of fluid in the mouth quickly. Once the patient becomes better hydrated, cooperation improves enough to take small sips from a cup. This method is time intensive and requires dedication. Encouragement from the physician is necessary to promote compliance.
• Antimicrobial therapy is indicated for some bacterial gastroenteritis infections. However, many are self-limited and do not require therapy. The following is a list of standard therapies:
  • Aeromonas species: Use cefixime and most third-generation and fourth-generation cephalosporins.
  • Bacillus species: No antibiotics are necessary for self-limited gastroenteritis, but vancomycin and clindamycin are first-line drugs for severe disease.
  • Campylobacter species: Erythromycin may shorten illness duration and shedding. Delaying therapy beyond 4 days from onset of symptoms appears to produce no clinical benefit.
  • C difficile: Discontinue potential causative antibiotics. If antibiotics cannot be stopped or this does not resolve diarrhea, use oral metronidazole or vancomycin. Vancomycin is reserved for seriously ill patients who do not respond to metronidazole.
  • C perfringens: Do not treat with antibiotics.
  • E coli: Antibiotic treatment appears to increase the likelihood of HUS developing. Consider antibiotics if diarrhea is moderate or severe. Trimethoprim-sulfamethoxazole is a first-line drug, but use a parenteral second-generation or third-generation cephalosporin for systemic complications.
  • Listeria species: No antibiotics are needed unless invasive disease occurs. Ampicillin and Bactrim are first-line drugs for invasive disease.
  • Plesiomonas species: Use trimethoprim-sulfamethoxazole or any cephalosporin.
  • Salmonella species: Antibiotic treatment prolongs carrier state and is associated with relapse; thus, treatment is not indicated for nontyphoid, uncomplicated diarrhea. Consider treatment for infants younger than 3 months and for high-risk patients, such as patients who are immunocompromised or have sickle cell disease. Ampicillin is recommended for drug-sensitive strains. Trimethoprim-sulfamethoxazole, fluoroquinolones, or third-generation cephalosporins (fluoroquinolones are not recommended for use in children) are also acceptable alternatives. S typhimurium T104 is a multidrug-resistant organism. Sensitivities from the cultured specimens are important to guide therapy.
  • Shigella species: Antibiotic treatment may shorten illness duration and shedding but does not prevent complications. Most mild infections will recover without antibiotics. Moderate to severe cases should be treated with antibiotics. Ampicillin is preferred for drug-sensitive strains. For ampicillin resistant strains or in cases of penicillin allergy, trimethoprim-sulfamethoxazole is the drug of choice, though resistance does occur. Fluoroquinolones may be considered in patients with highly resistant organisms.
  • Vibrio cholerae: Tetracycline is the usual antibiotic of choice, but resistance to it is increasing. Other antibiotics that are effective when V cholerae are sensitive to them include cotrimoxazole, erythromycin, doxycycline, chloramphenicol, and furazolidone.
  • Yersinia species: Treatment (ie, trimethoprim-sulfamethoxazole, fluoroquinolones, aminoglycosides) does not shorten disease duration and should be reserved for complicated cases.
• Antimotility agents are not indicated routinely for infectious diarrhea, (except for refractory cases of Cryptosporidium infection).
• Live Lactobacillus GG and heat-killed Lactobacillus LB reduce the duration of diarrhea in children when they are added to oral rehydration solution.

Consultations

• Certain organisms cause abdominal pain and bloody stools. Symptoms resembling appendicitis, hemorrhagic colitis, intussusception, or toxic megacolon may be appreciated. In such cases, obtain a consultation with a surgeon.
• Consider consultation with an infectious disease specialist, especially for any patient who is immunocompromised due to HIV infection, chemotherapy, or immunosuppressive drugs because atypical organisms are more likely and complications can be more serious and can fulminate.

Diet

• The BRAT diet (ie, bananas, rice, applesauce, toast) has been recommended for years. This diet is adequate during early convalescence, but, as the patient tolerates solid food, advance diet to provide adequate protein and caloric intake.
• Introduce lean meats and clear fluids as soon as possible. Dairy products are said to be better absorbed when given with proteins or complex carbohydrates.
• When feeding lactose-containing dairy products, carefully monitor for signs of malabsorption.
• Breast milk contains many substances that promote bowel growth and antagonize bacteria; thus, continue breastfeeding throughout the illness for infants.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Antibiotics

Along with the immune system, help destroy offending organisms.

FOLLOW-UP

Section 8 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Further Inpatient Care

• Admit neonates or young infants with moderate dehydration, suspected infection with enterohemorrhagic E coli, or bloody diarrhea.
• Oral rehydration is a time-consuming task that requires vigilance. Evaluate the caretaker of a child who requires oral rehydration for compliance. Consider admission if any doubt in potential compliance exists.
• Older patients, often with other illnesses, require careful observation and consideration for admission.

Further Outpatient Care

• Follow-up care depends on the severity of infection and the age of the patient.
• • Uncomplicated diarrhea may not require follow-up if the patient or caretaker is reliable and has adequate access to medical care if needed.
  • Monitor young children, elderly patients, and debilitated individuals closely to ensure complications do not occur.
  • Monitor patients requiring labor-intensive oral rehydration to ensure that the proper diet has been reintroduced.
  • Neonates require strict follow-up care within a few days of illness to ensure that malabsorption and dehydration do not occur.

Deterrence/Prevention

• Salmonella typhi vaccine is recommended for travelers to countries with a high incidence of this infection, persons with intimate exposure to a documented typhoid fever carrier, and workers with frequent exposure to these bacteria. Live attenuated, killed whole-cell, and capsular polysaccharide vaccines are available.
• Vibrio vaccine is available but only protects 50% of immunized persons for 3-6 months. It is not indicated for widespread use.
• In February 2006, the United States Food and Drug Administration (FDA) approved an oral vaccine for rotavirus (RotaTeq) for use in infants. It is currently the only vaccine approved in the United States for prevention of rotavirus gastroenteritis as of the date of this publication. On February 21, 2006, the American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP) recommended RotaTeq to be part of regularly scheduled childhood immunizations. RotaTeq is administered in a 3-dose series starting between age 6-12 wk and completing before 32 wk. Clinical trials demonstrated prevention of 74% of all rotavirus gastroenteritis cases, of nearly all severe rotavirus gastroenteritis cases, and of nearly all hospitalizations. Previously marketed rotavirus vaccine (RotaShield) was associated with intussusception, but RotaTeq did not show an increased risk compared with placebo in clinical trials.
• In April 2008, the FDA approved Rotarix, another oral vaccine, for prevention of rotavirus gastroenteritis. Rotarix administration is currently recommended as 2 separate doses to patients between 6 and 24 weeks of age. Rotarix was efficacious in a large study showing that it protected patients with severe rotavirus gastroenteritis as well as decreasing the rate of severe diarrhea or gastroenteritis of any cause.¹
• Avoidance of undercooked meats and seafood, as well as contaminated water supplies, when traveling may help reduce the risk of transmission of food and water-borne infectious causes of gastroenteritis and associated symptoms.

Complications

• Common complications that can occur with various organisms are as follows:
• • Aeromonas caviae - Intussusception, gram-negative sepsis, and HUS
  • Bacillus species - Fulminant liver failure (very rare) and rhabdomyolysis (very rare)
  • Campylobacter species - Bacteremia, meningitis, cholecystitis, urinary tract infection, pancreatitis, and Reiter syndrome
  • C difficile - Chronic diarrhea, toxic megacolon, and ileus
  • C perfringens serotype C - Enteritis necroticans
  • Enterohemorrhagic E coli - Hemorrhagic colitis
  • Enterohemorrhagic E coli O157:H7 - HUS
  • Listeria species - Bacteremia and meningitis
  • Plesiomonas species - Septicemia
  • Salmonella species - Enteric fever, bacteremia, meningitis, osteomyelitis, myocarditis, and Reiter syndrome
  • Shigella species - Seizures, HUS, perforation, and Reiter syndrome
  • Vibrio species - Rapid dehydration
  • Yersinia enterocolitica - Appendicitis, perforation, intussusception, peritonitis, toxic megacolon, cholangitis, bacteremia, and Reiter syndrome
• S typhi causes enteric fever. This syndrome has an insidious onset of malaise, fever, abdominal pain, and bradycardia. Diarrhea and rash (rose spots) appear after 1 week of symptoms. Bacteria may have disseminated at that time, and treatment is required to prevent systemic complications, such as hepatitis, myocarditis, cholecystitis, or GI bleeding.
• Damage to vascular endothelial cells by verotoxin causes HUS. Thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure are characteristic of HUS. Symptoms usually develop 1 week after onset of diarrhea, when organisms may be absent.
• Reiter syndrome can complicate acute infections. Arthritis, urethritis, conjunctivitis, and mucocutaneous lesions are characteristic. Affected individuals usually do not demonstrate all features.
• Carrier states are observed after some bacterial infections. After Salmonella diarrhea, 1-4% of individuals with nontyphoid and enteric fever infections become carriers. Carrier stage for Salmonella species is more likely to develop in females, infants, and individuals with biliary tract disease. Asymptomatic C difficile carriage may be seen in many hospitalized patients receiving antibiotics and in 50% of infants.
• Hyponatremic seizures can be avoided by rehydrating with oral rehydration solution instead of free water.
• A recent study suggests that infectious gastroenteritis may play a role in the initiation and/or exacerbation of inflammatory bowel disease. Similarly, irritable bowel syndrome may develop more often following bacterial gastroenteritis. This topic is highly controversial, and no conclusive evidence currently exists to support or refute this hypothesis.

Prognosis

• With proper management, prognosis is very good, especially in developed countries.
• Mortality predominantly is due to dehydration and secondary malnutrition from a protracted course. Treat severe dehydration with parenteral fluids.
• Once malnutrition from secondary malabsorption begins, prognosis becomes grim unless the patient is hospitalized and supplemental parenteral nutrition is started.
• Neonates and young infants are at particular risk for dehydration, malnutrition, and malabsorption syndromes.
• Even though the mortality rate is low in developed countries, people can, and do, die from complications. Prognosis in countries without modern medical care or for patients with serious preexisting medical conditions is more guarded.

Patient Education

• Education is most important for prevention and treatment.
• Proper oral rehydration therapy helps prevent dehydration and speed recovery of the intestinal mucosa.
• Diet restrictions that prevent secondary malabsorption are extremely important; relapse typically occurs due to diet noncompliance.
• Emphasize proper hygiene and food preparation practices to caretakers in order to prevent future infections and spread.
• For excellent patient education resources, visit eMedicine's Esophagus, Stomach, and Intestine Center and Public Health Center. Also, see eMedicine's patient education articles Gastroenteritis and Foreign Travel.

MISCELLANEOUS

Section 9 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical/Legal Pitfalls

• Dehydration is the most common complication from gastroenteritis in the United States. Continuing losses without compensatory intake can result in severe dehydration. In high-risk populations, maintain close follow-up in order to ensure proper therapy is provided. For example, oral rehydration is a time-consuming task that requires vigilance. If the physician has any doubt concerning the compliance of the caretaker with proper rehydration therapy, consider admission to the hospital.
• Chronic diarrhea and carbohydrate malabsorption can develop with a prolonged bout of diarrhea, especially if dietary concerns are not sustained.
• • Although some claim that changes in dietary regimen are not necessary, improper diet can result in prolonged recovery or development of carbohydrate malabsorption, especially if the acute episode is overshadowed by an undiagnosed chronic bacterial or malabsorption syndrome.
  • Thus, a prolonged course should prompt investigation of complicating factors. Results from tests such as stool acidity and reducing substances can indicate carbohydrate malabsorption. Failure to recognize this complication can result in significant rapid weight loss with wasting of fat and muscle mass.

Special Concerns

• Antibiotic resistance is increasing worldwide. Considering how critical antimicrobial therapy is in the management of moderate-to-severe bacterial gastroenteritis, it is crucial that health care providers continue to use antibiotics conservatively and only in patients for whom they are clearly indicated. National and international public health programs must continue to collect data to help define emerging resistant strains and to better guide future therapy.

REFERENCES

Section 10 of 10

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. Jan 5 2006;354(1):11-22. [Medline].
2. Centers for Disease Control and Prevention. Yersinia enterocolitica. www.cdc.gov. 2005;[Full Text].
3. Cody SH, Abbott SL, Marfin AA. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. May 19 1999;281(19):1805-10. [Medline].
4. Duggan C, Nurko S. "Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea. J Pediatr. Dec 1997;131(6):801-8. [Medline].
5. DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. Nov 1997;92(11):1962-75. [Medline].
6. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. May 2006;130(6):1588-94.
7. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. May 30 2006.
8. Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. Dec 1998;12(4):697-717. [Medline].
9. Guandalini S, Pensabene L, Zikri MA. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):54-60. [Medline].
10. Hamer DH, Gorbach SL. Infectious Diarrhea and Bacterial Food Poisoning. Sleisinger and Fordtran's: Gastrointestinal and Liver Disease, 6th Edition. 1998;1594-1632.
11. Lee LA, Gerber AR, Lonsway DR. Yersinia enterocolitica 0:3 infections in infants and children, associated with the household preparation of chitterlings. N Engl J Med. 1990;322:984-7.
12. Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting, diarrhea, and dehydration. Curr Opin Pediatr. Oct 1998;10(5):461-9. [Medline].
13. Marks MI. Infectious diarrhea: introduction and commentary. Pediatr Ann. Oct 1994;23(10):526-7. [Medline].
14. Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am. Feb 1997;15(1):157-77. [Medline].
15. Nataro JP, Steiner T, Guerrant RL. Enteroaggregative Escherichia coli. Emerg Infect Dis. Apr-Jun 1998;4(2):251-61. [Medline].
16. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med. Jun 2006;119(6 Suppl 1):S20-8; discussion S62-70.
17. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. Feb 27 1999;318(7183):565-6. [Medline].
18. Salminen S, Isolauri E, Onnela T. Gut flora in normal and disordered states. Chemotherapy. 1995;41 Suppl 1:5-15. [Medline].
19. Simakachorn N, Pichaipat V, Rithipornpaisarn P. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children [published erratum appears in J Pediatr Gastroenterol Nutr 2000 Feb;30(2):228]. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):68-72. [Medline].
20. Steffen R, Collard F, Tornieporth N. Epidemiology, etiology, and impact of traveler''s diarrhea in Jamaica. JAMA. Mar 3 1999;281(9):811-7. [Medline].
21. Streit JM, Jones RN, Toleman MA. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY An. Int J Antimicrob Agents. May 2006;27(5):367-75.
22. Sullivan PB. Nutritional management of acute diarrhea. Nutrition. Oct 1998;14(10):758-62. [Medline].
23. Trachtman H, Christen E. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Curr Opin Pediatr. Apr 1999;11(2):162-8. [Medline].
24. Wong CS, Jelacic S, Habeeb RL. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. Jun 29 2000;342(26):1930-6. [Medline].
25. World Health Organization. Cholera, Fact Sheet No. 107. www.who.int. 2000;[Full Text].
26. World Health Organization. Drug-resistant Salmonella, Fact sheet No. 139. www.who.int. 2005;[Full Text].

Article Last Updated: Apr 28, 2008